CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 26 enrolled
Drug / intervention
Aldesleukindrug
Likely dose
Not stated in record
Key inclusion· 2
  • ✓ECOG performance status 0 or 1
  • ✓Adequate organ function
Key exclusion· 3
  • ✕Prior treatment with any form of IL-2
  • ✕Pregnancy or lactation
  • ✕Organ transplant

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00414765
NCT00414765Phase 4Completed
CompareCT.gov

Open-label Pharmacokinetic Trial of Aldesleukin (Rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma or Metastatic Melanoma With Immunologic Correlative Studies

Novartis Pharmaceuticals·interventional·Posted Dec 22, 2006·Updated Jun 8, 2021

In Brief

A Phase 4 clinical trial evaluating Aldesleukin for Metastatic Renal Cell Carcinoma and Metastatic Melanoma. Completed, enrolled 26 participants across 4 sites.

Detailed Summary

This study evaluated the pharmacokinetics of aldesleukin in participants with metastatic renal cell cancer or metastatic melanoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Renal Cell Carcinoma, Metastatic Melanoma
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 22, 2006
Enrollment StartSep 3, 2008
Primary CompletionMar 28, 2010
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.5 years ago

Interventions

Aldesleukindrug